Major Shareholder Makes Bold Move with Passage Bio Stock Purchase!

New insider activity at Passage Bio ( (PASG) ) has taken place on July 24, 2025.

Lynx1 Capital Management LP, a significant shareholder, has made a notable investment by purchasing 128,848 shares of Passage Bio stock. This acquisition is valued at $733,526, indicating a strong confidence in the company’s future prospects.

Recent Updates on PASG stock

Passage Bio recently announced a 1-for-20 reverse stock split of its common stock, effective July 14, 2025, to comply with Nasdaq’s minimum bid price requirement. This corporate action, approved by stockholders and the Board, aims to reduce the number of outstanding shares without affecting ownership percentages or authorized shares. The move is intended to regain compliance with Nasdaq’s minimum bid price rule of $1.00 per share. Despite the company’s financial challenges, including no revenue and significant cash burn, analysts maintain a Buy rating due to promising clinical trial results and strategic adjustments. The stock was recently halted pending news, indicating potential significant developments. Technical indicators currently suggest a neutral to bearish sentiment.

Spark’s Take on PASG Stock

According to Spark, TipRanks’ AI Analyst, PASG is a Neutral.

Passage Bio scores moderately low due to its financial challenges, including no revenue and significant cash burn. However, a strong balance sheet and recent corporate event announcements, including program advancements and extended cash runway, provide some optimism. Technical indicators suggest a neutral to bearish sentiment, and traditional valuation metrics are limited due to the company’s stage and lack of profitability.

To see Spark’s full report on PASG stock, click here.

More about Passage Bio

YTD Price Performance: -49.03%

Average Trading Volume: 33,418

Technical Sentiment Signal: Sell

Current Market Cap: $18.04M